deltatrials
Completed PHASE2 NCT03727880

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

A Randomized Phase II Study of Pembrolizumab With or Without Defactinib, a Focal Adhesion Kinase Inhibitor Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma (PDAC)

Sponsor: Lei Zheng

Conditions Pancreatic Ductal Adenocarcinoma Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions Defactinib Pembrolizumab
Updated 24 times since 2018 Last updated: Jan 16, 2026 Started: Jun 4, 2019 Primary completion: Jan 15, 2025 Completion: Jan 15, 2025

Listed as NCT03727880, this PHASE2 trial focuses on Pancreatic Ductal Adenocarcinoma and Resectable Pancreatic Ductal Adenocarcinoma (PDAC) and remains completed. Sponsored by Lei Zheng, it has been updated 24 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

24 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Sep 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Jun 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  4. May 2025 — Jun 2025 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Oct 2024 — May 2025 [monthly]

    Recruiting PHASE2

▶ Show 19 earlier versions

  1. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  3. Feb 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  4. Oct 2023 — Feb 2024 [monthly]

    Recruiting PHASE2

  5. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  6. Mar 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  7. Jun 2022 — Mar 2023 [monthly]

    Recruiting PHASE2

  8. Apr 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  9. Sep 2021 — Apr 2022 [monthly]

    Recruiting PHASE2

  10. Apr 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  11. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  12. Feb 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  13. Aug 2019 — Feb 2020 [monthly]

    Recruiting PHASE2

  14. Jun 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  15. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  16. Apr 2019 — May 2019 [monthly]

    Not Yet Recruiting PHASE2

  17. Mar 2019 — Apr 2019 [monthly]

    Not Yet Recruiting PHASE2

  18. Jan 2019 — Mar 2019 [monthly]

    Not Yet Recruiting PHASE2

  19. Dec 2018 — Jan 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Lei Zheng
  • Merck Sharp & Dohme LLC
  • Verastem, Inc.
Data source: The University of Texas Health Science Center at San Antonio

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Baltimore, United States
  • • Los Angeles, United States
  • • San Antonio, United States